Skip to main content

Table 3 Enrolment number and publishing timeline for completed studies

From: Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009

Registration number Type of study Treatment Planned enrolment (n) Total patients1 (n) H1N1 patients1 (n) First patient enrolment1 (month, year) Last patient enrolment1 (month, year) Date published (month, year)
Enrolment commenced before pandemic
 NCT00298233 Phase 2 Oseltamivir 400 326 72 Apr. 2007 Feb. 2010 May 2013 [8]
 NCT00391768 Phase 1/2 Oseltamivir 108 87 37 Jan. 2007 Apr. 2010 Mar. 2013 [9]
Enrolment commenced during pandemic
 NCT00949533 Phase 3 Oseltamivir 125 37 Unknown Aug. 2009 Oct. 2010 Apr. 2016 (Unp)
 NCT00957996 Phase 3 Peramivir 300 127 94 Oct. 2009 Oct. 2010 Aug. 2013 [10]
 NCT01199744 Prospective cohort Zanamivir N/R 1575 Unknown Nov. 2009 Apr. 2010 Mar. 2011(Unp)
 NCT01014988 Phase 2 Zanamivir 150 130 92 Nov. 2009 Sep. 2011 Feb. 2014 [11]
 NCT01052961 Phase 4 Oseltamivir 400 155 34 Jan. 2010 Jun. 2012 Dec. 2013 [12]
 NCT01050257 Phase 3 Oseltamivir 200 118 Unknown Jan. 2010 Sep. 2012 Aug. 2013 (Unp)
 NCT01068912 Phase 2 Favipiravir 384 530 110 Feb. 2010 May 2012 Feb. 2014 (Unp)
  1. Enrolment number and publishing timeline for completed studies where results are published in the literature (date followed by reference) or on the clinical trials registration site (date followed by Unp)
  2. N/R not reported
  3. 1Where conflict existed between numbers in the clinical trial record and publication, publication numbers were used